Respiratory InfectionsCommunity-acquired Pneumonia and Acute Respiratory Distress Syndrome: Prevalence, Risk, and PrognosisCillóniz, Catia PhD*; Nicolini, Antonello MD†; Luque, Nestor MD‡; Torres, Antoni MD*Author Information *Department of Pneumology, Institut Clinic del Tórax, Hospital Clinic of Barcelona, Institut d’Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), University of Barcelona (UB), Ciber de Enfermedades Respiratorias (Ciberes), Barcelona, Spain †Respiratory Medicine Unit, Internal Medicine Department, General Hospital, Sestri Levante, Italy ‡Unit of Strategic Interventions in Public Health/National Institute of Health, Lima, Peru Supported by Ciber de Enfermedades Respiratorias (CibeRes CB06/06/0028). The funding sources had no role in the manuscript. Disclosure: C.C. is in receipt of a Postdoctoral Grant (Strategic plan for research and innovation in health-PERIS 2016 to 2020). The remaining authors declare that they have no conflicts of interest. Address correspondence to: Catia Cillóniz, PhD, Department of Pneumology, Hospital Clinic of Barcelona, C/Villarroel, 170 08036 Barcelona, Spain. E-mail: email@example.com. Clinical Pulmonary Medicine: May 2018 - Volume 25 - Issue 3 - p 100-106 doi: 10.1097/CPM.0000000000000262 Buy Metrics Abstract Severe community-acquired pneumonia is the most common cause of acute respiratory distress syndrome (ARDS). Despite multiple improvements in the last 10 years, this syndrome remains highly prevalent worldwide and is associated with high mortality and long-term morbidity rates. Several factors are related to the increasing risk of ARDS. Clinicians should be familiar with the use of lung-protective strategies and the mechanism of ventilator-induced lung injury, as ventilator management of ARDS is complex. Clinical trials are now needed, to investigate adjunctive therapies in patients with severe pneumonia and ARDS, such as systemic corticosteroids. Copyright © 2018 Wolters Kluwer Health, Inc. All rights reserved.